Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Table 3 Resource use and costs for patients with HCC potentially eligible for second-line therapy^a

Variable	Subgroup #3^b		Subgroup #4^c		Subgroup #3 and #4
	[n = 87]		[n = 30]		[n = 117]
	Utilisation, n (SD)	Cost per patient (€)	Utilisation, n (SD)	Cost per patient (€)	Utilisation, n (SD)	Cost per patient (€)
Hospital care^d	1.86 (2.37)	6556.25	1.30 (1.58)	6271.95	1.72 (2.20)	6483.36
Outpatient visits	19.05 (19.43)	862.54	26.77 (23.11)	789.69	21.03 (20.61)	843.86
Outpatient prescriptions	24.94 (24.41)	1451.77	27.90 (27.56)	8025.81	25.70 (25.17)	3137.42
Other benefits^e	5.60 (6.75)	671.12	5.37 (11.12)	730.96	5.54 (8.04)	686.46
Remedies	0.03 (0.18)	0.64	0.00 (0.00)	0.00	0.03 (0.16)	0.48
Total	–	9542.32	–	15,818.41	–	11,151.58

Data are presented as mean (standard deviation, SD) values
HCC hepatocellular carcinoma
^aResource utilisation and costs in the 12 months after the end of sorafenib treatment
^bPatients who died within the observation period but not under sorafenib therapy (i.e. more than 70 days between the last sorafenib prescription and death)
^cPatients who were still alive at the end of the observation period and at least 70 days passed between the last prescription of sorafenib and the end of the observation period
^dCosts include all hospital-related costs – admissions and ambulatory treatments in hospital
^eAdditional benefits paid by the German statutory health insurance (e.g. statutory pension fund benefits, therapeutic appliances, travelling costs, nursing care benefits, home healthcare)

ISSN: 2191-1991